Ameriprise’s Enzo Biochem, Inc. ENZ Stock Holding History

Ameriprise’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-2,238	Closed	-$12K	–	4477
2014 Q3	$12K	Buy	2,238 +1,500	+203%	+$8K	﹤0.01%	4751
2014 Q2	$4K	Hold	738	–	–	﹤0.01%	5020
2014 Q1	$3K	Hold	738	–	–	﹤0.01%	4956
2013 Q4	$2K	Hold	738	–	–	﹤0.01%	4898
2013 Q3	$2K	Sell	738 -123,863	-99%	-$294K	﹤0.01%	5417
2013 Q2	$260K	Buy	+124,601	New	+$275K	﹤0.01%	2990

Other funds holding ENZ

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's ENZ Position: Q4 2014 in Review

Ameriprise sold out of Enzo Biochem, Inc. (ENZ) in Q4 2014, closing a stake of 2,238 shares — an estimated $12K sold.

Ameriprise first reported a position in ENZ in Q2 2013 and held it in 6 quarters. The position peaked at $260K in Q2 2013. 87 funds tracked by Wall St. Rank hold ENZ as of Q4 2014.

Ameriprise reported no remaining Enzo Biochem, Inc. position as of Q4 2014 after selling out during the quarter.
Ameriprise sold 2,238 Enzo Biochem, Inc. shares in Q4 2014, an estimated $12K.
Ameriprise first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 6 quarters.
Ameriprise's Enzo Biochem, Inc. position peaked at $260K in Q2 2013.
87 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2014.

Based on Ameriprise's 13F filing for Q4 2014, filed 13 Feb 2015.